ArticleFrontiers in immunology2025
Mitochondrial damage and IL-1β production in monocytes caused by
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prohibitins: emerging host targets of bacteria and viruses at the plasma membrane, mitochondria, and cytoplasm.Microbial cell (Graz, Austria) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The intracellular proliferation of Methods: In the infection of human monocytic cell line THP-1 cells with the Results: In the infection of THP-1 cells with the NcGRA7KO parasite, decreased IL-1β release was observed compared with Nc1 infection. Transfection with plasmids for reconstitution of the NLRP3 inflammasome enhanced IL-1b production via additional transfection with NcGRA7 cDNA. NLRP3 inhibitor, CASP1 inhibitor, and NF-κB inhibitor significantly suppressed IL-1β production induced by Nc-1 infection, whereas no inhibitory effect was observed in NcGRA7KO-infected cells. Furthermore, treatment with any of the inhibitors led to a reduction in TNF-α production in both Nc-1- and NcGRA7KO-infected cells. Western blot analysis of phosphorylated NF-κB p65 demonstrated that Discussion: These findings indicate that NcGRA7 does not directly modulate NF-κB activation but likely enhances the production of IL-1β and TNF-α through post-transcriptional mechanisms, thereby contributing to the upregulation of NLRP3 expression. Moreover, our results suggest that NcGRA7 influences both the NF-κB and inflammasome pathways through its interaction with host cell prohibitins. Elucidating the roles of PHB1 and NcGRA7 will provide new insights into the host-parasite interactions underlying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.